We identified an individual with squamous cell carcinoma of the head and neck who was found to harbor an extracellular FGFR2 mutation (p.P253R) in a biopsy specimen…He began daily treatment with 800 mg pazopanib...A follow up visit 12 days later showed a marked reduction in tumor size (Figure 5C, right panel)....This correlative observation does not definitively identify FGFR2 as the target of pazopanib, but we believe that this result provides compelling rationale to continue to pursue treatment of FGFR2-mutated tumors with anti-FGFR targeted therapies.